81 FR 59642 - Findings of Research Misconduct
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary Federal Register Volume 81, Issue 168 (August 30, 2016)
Office of the Secretary
Federal Register Volume 81, Issue 168 (August 30, 2016)
| Page Range | 59642-59643 | |
| FR Document | 2016-20834 |
[Federal Register Volume 81, Number 168 (Tuesday, August 30, 2016)] [Notices] [Pages 59642-59643] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-20834] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Andrew R. Cullinane, Ph.D., National Institutes of Health: Based on Respondent's admission, an assessment conducted by the National Institutes of Health (NIH), and analysis conducted by ORI in its oversight review, ORI found that Dr. Andrew R. Cullinane, former postdoctoral fellow, Medical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, engaged in research misconduct in research supported by NHGRI, NIH. ORI found that Respondent engaged in research misconduct by reporting falsified and/or fabricated data in the following two (2) publications and one (1) submitted manuscript:Am. J. Hum. Genet. 88(6):778-787, 2011 (hereafter referred to as ``Paper 1'') Neurology 86(14):1320-1328, 2016 (hereafter referred to as ``Paper 2'') ``RAB11FIP1, Mutated in HPS-10, Interacts with BLOC-1 to Mitigate Recycling of Melanogenic Proteins.'' Submitted for publication to The Journal of Clinical Investigations, Cell, Nature Biology, Molecular Cell, and Nature Genetics (hereafter referred to as ``Manuscript 1'') ORI found that Respondent knowingly falsified and/or fabricated data and related images by alteration and/or reuse and/or relabeling of experimental data. Specifically: in Paper 1, Respondent falsified and/or fabricated the results in Figure 3C by using the same gel images to represent expression of PLDN in fibroblasts and melanocytes in Paper 2, Respondent falsified and/or fabricated the results in Figure 2A by erasure of a band in the blot image for LYST/CHD-4 that was present in the original data in Manuscript 1, Respondent falsified and/or fabricated the results in Western blot data by reuse and relabeling, duplication, and/ or manipulation in Figures 2B, 2D, 2E, 3A-C, 4C, 4E, 4G, 5B, 6A-C, 7A, 7D, 7G, 7J, and Supplemental Figure 3, and Respondent falsified and/or fabricated the results by reuse and relabeling of centrifuge tubes to represent different experiments in Figures 1D, 7C, 7F, 7I, 7L, and Supplemental Figure 2 Dr. Cullinane has entered into a Voluntary Settlement Agreement with ORI and NIH, in which he voluntarily agreed: (1) To have his research supervised for a period of three (3) years beginning on July 22, 2016; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, the institution employing him must submit a plan for supervision of his duties to ORI for approval. The plan for supervision must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that he will not participate in any PHS-supported research until a plan for supervision is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that for a period of three (3) years beginning on July 22, 2016, any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) to exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on July 22, 2016; and (4) as a condition of the Agreement, Respondent agreed to the retraction or correction of: Am. J. Hum. Genet. 88(6):778-787, 2011 [[Page 59643]] Neurology 86(14):1320-1328, 2016 FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. Kathryn M. Partin, Director, Office of Research Integrity. [FR Doc. 2016-20834 Filed 8-29-16; 8:45 am] BILLING CODE 4150-31-P
![59642 Federal Register / Vol. 81, No. 168 / Tuesday, August 30, 2016 / Notices
Burden Statement: Burden in this technology and systems for the purpose data sources; (7) completing and
context means the time expended by of collecting, validating and verifying reviewing the collection of information;
persons to generate, maintain, retain, information; (3) processing and and (8) transmitting or otherwise
disclose or provide the information maintaining information; (4) disclosing disclosing the information. The total
requested. This includes (1) the time and providing information; (5) training annual burden hours estimated for this
needed to review instructions; (2) to personnel to be able to respond to a ICR are summarized in the table below.
develop, acquire, install and utilize collection of information; (6) searching
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Average
Number of
Number of Total burden per Total burden
Form name responses per
respondents responses response hours
respondent (in hours)
Baseline Pre-TED (Transplant Essential Data) ................... 200 44 8,800 1.15 10,120
Product Form (includes Infusion, HLA, and Infectious Dis-
ease Marker inserts) ........................................................ 200 33 6,600 1 6,600
100-Day Post-TED ............................................................... 200 44 8,800 1.25 11,000
6-Month Post-TED ............................................................... 200 36 7,200 1.15 8,280
12-Month Post-TED ............................................................. 200 32 6,400 1.15 7,360
Annual Post-TED ................................................................. 200 110 22,000 1.15 25,300
* Total ............................................................................ 200 ........................ 59,800 ........................ 68,660
* The Total of 200 is the number of centers completing the form. The same group of 200 centers completes each of the forms.
Jason E. Bennett, Recycling of Melanogenic Proteins.’’ Service (PHS) support for a research
Director, Division of the Executive Secretariat. Submitted for publication to The project on which Respondent’s
[FR Doc. 2016–20758 Filed 8–29–16; 8:45 am] Journal of Clinical Investigations, Cell, participation is proposed and prior to
BILLING CODE 4165–15–P Nature Biology, Molecular Cell, and Respondent’s participation in any
Nature Genetics (hereafter referred to capacity on PHS-supported research, the
as ‘‘Manuscript 1’’) institution employing him must submit
DEPARTMENT OF HEALTH AND ORI found that Respondent a plan for supervision of his duties to
HUMAN SERVICES knowingly falsified and/or fabricated ORI for approval. The plan for
data and related images by alteration supervision must be designed to ensure
Office of the Secretary and/or reuse and/or relabeling of the scientific integrity of Respondent’s
experimental data. Specifically: research contribution; Respondent
Findings of Research Misconduct
• in Paper 1, Respondent falsified and/ agreed that he will not participate in
AGENCY: Office of the Secretary, HHS. or fabricated the results in Figure 3C any PHS-supported research until a plan
ACTION: Notice. by using the same gel images to for supervision is submitted to and
represent expression of PLDN in approved by ORI; Respondent agreed to
SUMMARY: Notice is hereby given that fibroblasts and melanocytes maintain responsibility for compliance
the Office of Research Integrity (ORI) • in Paper 2, Respondent falsified and/ with the agreed upon supervision plan;
has taken final action in the following or fabricated the results in Figure 2A (2) that for a period of three (3) years
case: by erasure of a band in the blot image beginning on July 22, 2016, any
Andrew R. Cullinane, Ph.D., National for LYST/CHD–4 that was present in institution employing him shall submit,
Institutes of Health: Based on the original data in conjunction with each application for
Respondent’s admission, an assessment • in Manuscript 1, Respondent falsified PHS funds, or report, manuscript, or
conducted by the National Institutes of and/or fabricated the results in abstract involving PHS-supported
Health (NIH), and analysis conducted by Western blot data by reuse and research in which Respondent is
ORI in its oversight review, ORI found relabeling, duplication, and/or involved, a certification to ORI that the
that Dr. Andrew R. Cullinane, former manipulation in Figures 2B, 2D, 2E, data provided by Respondent are based
postdoctoral fellow, Medical Genetics 3A–C, 4C, 4E, 4G, 5B, 6A–C, 7A, 7D, on actual experiments or are otherwise
Branch, National Human Genome 7G, 7J, and Supplemental Figure 3, legitimately derived and that the data,
Research Institute (NHGRI), NIH, and Respondent falsified and/or procedures, and methodology are
engaged in research misconduct in fabricated the results by reuse and accurately reported in the application,
research supported by NHGRI, NIH. relabeling of centrifuge tubes to report, manuscript, or abstract;
ORI found that Respondent engaged represent different experiments in (3) to exclude himself from serving in
in research misconduct by reporting Figures 1D, 7C, 7F, 7I, 7L, and any advisory capacity to PHS including,
falsified and/or fabricated data in the Supplemental Figure 2 but not limited to, service on any PHS
following two (2) publications and one Dr. Cullinane has entered into a advisory committee, board, and/or peer
(1) submitted manuscript: Voluntary Settlement Agreement with review committee, or as a consultant for
mstockstill on DSK3G9T082PROD with NOTICES
• Am. J. Hum. Genet. 88(6):778–787, ORI and NIH, in which he voluntarily a period of three (3) years, beginning on
2011 (hereafter referred to as ‘‘Paper agreed: July 22, 2016; and
1’’) (1) To have his research supervised (4) as a condition of the Agreement,
• Neurology 86(14):1320–1328, 2016 for a period of three (3) years beginning Respondent agreed to the retraction or
(hereafter referred to as ‘‘Paper 2’’) on July 22, 2016; Respondent agreed to correction of:
• ‘‘RAB11FIP1, Mutated in HPS–10, ensure that prior to the submission of an • Am. J. Hum. Genet. 88(6):778–787,
Interacts with BLOC–1 to Mitigate application for U.S. Public Health 2011
VerDate Sep<11>2014 20:04 Aug 29, 2016 Jkt 238001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\30AUN1.SGM 30AUN1](https://thefederalregister.org/doc/81_FR_59810/page/1.svg)
![Federal Register / Vol. 81, No. 168 / Tuesday, August 30, 2016 / Notices 59643
• Neurology 86(14):1320–1328, 2016 will focus on the Diabetes and would constitute a clearly unwarranted
FOR FURTHER INFORMATION CONTACT: Neurocognition. invasion of personal privacy.
Director, Office of Research Integrity, Any member of the public interested Name of Committee: National Institute on
1101 Wootton Parkway, Suite 750, in presenting oral comments to the Aging Initial Review Group, Behavior and
Rockville, MD 20852, (240) 453–8200. Committee should notify the contact Social Science of Aging Review Committee.
person listed on this notice at least 10 Date: September 29–30, 2016.
Kathryn M. Partin, days in advance of the meeting. Time: 4:00 p.m. to 2:00 p.m.
Director, Office of Research Integrity. Interested individuals and Agenda: To review and evaluate grant
[FR Doc. 2016–20834 Filed 8–29–16; 8:45 am] representatives or organizations should applications.
BILLING CODE 4150–31–P submit a letter of intent, a brief Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
description of the organization Wisconsin Avenue, Bethesda, MD 20814.
represented, and a written copy of their Contact Person: Kimberly Firth, Ph.D.,
DEPARTMENT OF HEALTH AND oral presentation in advance of the National Institute on Aging, Gateway
HUMAN SERVICES meeting. Only one representative of an Building, 7201 Wisconsin Avenue, Suite
organization will be allowed to present; 2W200, Bethesda, MD 20892, 301–402–7702,
National Institutes of Health
oral comments and presentations will be kimberly.firth@nih.gov.
Notice of Diabetes Mellitus Interagency limited to a maximum of 5 minutes. Name of Committee: National Institute on
Coordinating Committee Meeting Printed and electronic copies are Aging Initial Review Group, Clinical Aging
requested for the record. In addition, Review Committee.
SUMMARY: The Diabetes Mellitus any interested person may file written Date: September 29–30, 2016.
Interagency Coordinating Committee comments with the Committee by Time: 4:00 p.m. to 1:00 p.m.
(DMICC) will hold a meeting on Agenda: To review and evaluate grant
forwarding their statement to the applications.
September 12, 2016. The subject of the contact person listed on this notice. The
meeting will be the ‘‘Diabetes and Place: Doubletree Hotel Bethesda,
statement should include the name, (Formerly Holiday Inn Select), 8120
Neurocognition.’’ The meeting is open address, telephone number and when Wisconsin Avenue, Bethesda, MD 20814.
to the public. applicable, the business or professional Contact Person: Alicja L. Markowska,
DATES: The meeting will be held on affiliation of the interested person. Ph.D., DSC, National Institute on Aging,
September 12, 2016; from 1:00 p.m. to Because of time constraints for the National Institutes of Health, Gateway
4:30 p.m. Individuals wanting to present meeting, oral comments will be allowed Building 2W200, 7201 Wisconsin Avenue,
oral comments must notify the contact on a first-come, first-serve basis. Bethesda, MD 20892, 301–496–9666,
person at least 10 days before the markowsa@nia.nih.gov.
Members of the public who would
meeting date. like to receive email notification about (Catalogue of Federal Domestic Assistance
ADDRESSES: The meeting will be held in Program Nos. 93.866, Aging Research,
future DMICC meetings should register
National Institutes of Health, HHS)
the Democracy 2 Building at 6707 for the listserv available on the DMICC
Democracy Blvd., Bethesda, MD, in Web site, www.diabetescommittee.gov. Dated: August 24, 2016.
Conference Room 7050. Dated: August 24, 2016.
Melanie J. Gray,
FOR FURTHER INFORMATION CONTACT: For Program Analyst, Office of Federal Advisory
B. Tibor Roberts,
further information concerning this Committee Policy.
Executive Secretary, DMICC, Office of
meeting, see the DMICC Web site, Scientific Program and Policy Analysis,
[FR Doc. 2016–20727 Filed 8–29–16; 8:45 am]
www.diabetescommittee.gov, or contact National Institute of Diabetes and Digestive BILLING CODE 4140–01–P
Dr. B. Tibor Roberts, Executive and Kidney Diseases, National Institutes of
Secretary of the Diabetes Mellitus Health.
Interagency Coordinating Committee, [FR Doc. 2016–20824 Filed 8–29–16; 8:45 am] DEPARTMENT OF HEALTH AND
National Institute of Diabetes and BILLING CODE 4140–01–P
HUMAN SERVICES
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room National Institutes of Health
9A19, MSC 2560, Bethesda, MD 20892– DEPARTMENT OF HEALTH AND
2560, telephone: 301–496–6623; FAX: National Institute of Mental Health;
HUMAN SERVICES Notice of Closed Meeting
301–480–6741; email: dmicc@
mail.nih.gov. National Institutes of Health Pursuant to section 10(d) of the
SUPPLEMENTARY INFORMATION: The Federal Advisory Committee Act, as
National Institute on Aging; Notice of amended (5 U.S.C. App.), notice is
DMICC, chaired by the National
Closed Meetings hereby given of the following meeting.
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising Pursuant to section 10(d) of the The meeting will be closed to the
members of the Department of Health Federal Advisory Committee Act, as public in accordance with the
and Human Services and other federal amended (5 U.S.C. App.), notice is provisions set forth in sections
agencies that support diabetes-related hereby given of the following meetings. 552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
activities, facilitates cooperation, The meetings will be closed to the as amended. The grant applications and
communication, and collaboration on public in accordance with the the discussions could disclose
diabetes among government entities. provisions set forth in sections confidential trade secrets or commercial
DMICC meetings, held several times a 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., property such as patentable material,
mstockstill on DSK3G9T082PROD with NOTICES
year, provide an opportunity for as amended. The grant applications and and personal information concerning
Committee members to learn about and the discussions could disclose individuals associated with the grant
discuss current and future diabetes confidential trade secrets or commercial applications, the disclosure of which
programs in DMICC member property such as patentable material, would constitute a clearly unwarranted
organizations and to identify and personal information concerning invasion of personal privacy.
opportunities for collaboration. The individuals associated with the grant Name of Committee: National Institute of
September 12, 2016 DMICC meeting applications, the disclosure of which Mental Health Special Emphasis Panel.
VerDate Sep<11>2014 20:04 Aug 29, 2016 Jkt 238001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\30AUN1.SGM 30AUN1](https://thefederalregister.org/doc/81_FR_59810/page/2.svg)
Document Created: 2018-02-09 11:41:53
Document Modified: 2018-02-09 11:41:53
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. | |
| FR Citation | 81 FR 59642 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR